Idiopathic Multicentric Castleman's Disease Clinical Trial
Official title:
Bortezomib, Cyclophosphamide and Dexamethasone (BCD) in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) : a Prospective, Single-center, Single-arm, Phase-II Pilot Trial
To explore the effectiveness and safety of bortezomib, cyclophosphamide and dexamethasone (BCD regimen) in newly diagnosed idiopathic Multicentric Castleman's disease (iMCD) patients.
This will be a single center, open-labeled, single arm, phase-II pilot study. The treatment and the response evaluation phase will last from the time of enrollment up to 21 months (evaluation will be carried out every 3 months in the first 9 months and every 6 months from Month 9 to Month 21). The maintenance and follow-up phase to assess for progression of disease will last from 21 months to 45 months after enrollment (evaluation will be carried out every 12 months). The total study duration will be 4 years after the last patient starts study medication. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05995834 -
Producing a Novel Symptom Burden Scale for People Living With Idiopathic Multicentric Castleman Disease (ISBUS)
|
||
Terminated |
NCT04838860 -
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
|
Phase 2 | |
Recruiting |
NCT04743687 -
Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial
|
Phase 2 | |
Recruiting |
NCT05345522 -
A Study of Anti-IL-6R mAb Injection in Patients With iMCD
|
Phase 2 |